Literature DB >> 11008906

Empirical Bayes adjustments for multiple results in hypothesis-generating or surveillance studies.

K Steenland1, I Bray, S Greenland, P Boffetta.   

Abstract

Traditional methods of adjustment for multiple comparisons (e.g., Bonferroni adjustments) have fallen into disuse in epidemiological studies. However, alternative kinds of adjustment for data with multiple comparisons may sometimes be advisable. When a large number of comparisons are made, and when there is a high cost to investigating false positive leads, empirical or semi-Bayes adjustments may help in the selection of the most promising leads. Here we offer an example of such adjustments in a large surveillance data set of occupation and cancer in Nordic countries, in which we used empirical Bayes (EB) adjustments to evaluate standardized incidence ratios (SIRs) for cancer and occupation among craftsmen and laborers. For men, there were 642 SIRs, of which 138 (21%) had a P < 0.05 (13% positive with SIR > 1.0 and 8% negative with SIR < or = 1.0) when testing the null hypothesis of no cancer/occupation association; some of these were probably due to confounding by nonoccupational risk factors (e.g., smoking). After EB adjustments, there were 95 (15%) SIRs with P < 0.05 (10% positive and 5% negative). For women, there were 373 SIRs, of which 37 (10%) had P < 0.05 before adjustment (6% positive and 4% negative) and 13 (3%) had P < 0.05 after adjustment (2% positive and 1% negative). Several known associations were confirmed after EB adjustment (e.g., pleural cancer among plumbers, original SIR 3.2 (95% confidence interval, 2.5-4.1), adjusted SIR 2.0 (95% confidence interval, 1.6-2.4). EB can produce more accurate estimates of relative risk by shrinking imprecise outliers toward the mean, which may reduce the number of false positives otherwise flagged for further investigation. For example, liver cancer among chimney sweepers was reduced from an original SIR of 2.2 (range, 1.1-4.4) to an adjusted SIR of 1.1 (range, 0.9-1.4). A potentially important future application for EB is studies of gene-environment-disease interactions, in which hundreds of polymorphisms may be evaluated with dozens of environmental risk factors in large cohort studies, producing thousands of associations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008906

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  29 in total

Review 1.  Sequences associated with human iris pigmentation.

Authors:  Tony Frudakis; Matthew Thomas; Zach Gaskin; K Venkateswarlu; K Suresh Chandra; Siva Ginjupalli; Sitaram Gunturi; Sivamani Natrajan; Viswanathan K Ponnuswamy; K N Ponnuswamy
Journal:  Genetics       Date:  2003-12       Impact factor: 4.562

2.  Integrative assessment of multiple pesticides as risk factors for non-Hodgkin's lymphoma among men.

Authors:  A J De Roos; S H Zahm; K P Cantor; D D Weisenburger; F F Holmes; L F Burmeister; A Blair
Journal:  Occup Environ Med       Date:  2003-09       Impact factor: 4.402

3.  Association of Parkinson's disease with industry sectors: a French nationwide incidence study.

Authors:  Tim Vlaar; Sofiane Kab; Yannick Schwaab; Nadine Fréry; Alexis Elbaz; Frédéric Moisan
Journal:  Eur J Epidemiol       Date:  2018-05-05       Impact factor: 8.082

4.  Empirical Bayes and semi-Bayes adjustments for a vast number of estimations.

Authors:  Ulf Strömberg
Journal:  Eur J Epidemiol       Date:  2009-10-08       Impact factor: 8.082

5.  Clopidogrel Drug Interactions and Serious Bleeding: Generating Real-World Evidence via Automated High-Throughput Pharmacoepidemiologic Screening.

Authors:  Charles E Leonard; Meijia Zhou; Colleen M Brensinger; Warren B Bilker; Samantha E Soprano; Thanh Phuong Pham Nguyen; Young Hee Nam; Jordana B Cohen; Sean Hennessy
Journal:  Clin Pharmacol Ther       Date:  2019-07-04       Impact factor: 6.875

6.  Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury.

Authors:  Charles E Leonard; Colleen M Brensinger; Thanh Phuong Pham Nguyen; John R Horn; Sophie Chung; Warren B Bilker; Sascha Dublin; Samantha E Soprano; Ghadeer K Dawwas; David W Oslin; Douglas J Wiebe; Sean Hennessy
Journal:  Biomed Pharmacother       Date:  2020-07-30       Impact factor: 6.529

7.  Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer.

Authors:  Timothy L Lash; Soe Soe Thwin; Marianne Ulcickas Yood; Ann M Geiger; Jaclyn Bosco; Virginia P Quinn; Terry S Field; Pamala A Pawloski; Rebecca A Silliman
Journal:  Breast Cancer Res Treat       Date:  2014-03-01       Impact factor: 4.872

8.  Leukaemia and occupation: a New Zealand Cancer Registry-based case-control Study.

Authors:  David McLean; Andrea 't Mannetje; Evan Dryson; Chris Walls; Fiona McKenzie; Milena Maule; Soo Cheng; Chris Cunningham; Hans Kromhout; Paolo Boffetta; Aaron Blair; Neil Pearce
Journal:  Int J Epidemiol       Date:  2008-10-25       Impact factor: 7.196

9.  No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.

Authors:  Thomas P Ahern; Lars Pedersen; Deirdre P Cronin-Fenton; Henrik Toft Sørensen; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

10.  Lung cancer and occupation in a population-based case-control study.

Authors:  Dario Consonni; Sara De Matteis; Jay H Lubin; Sholom Wacholder; Margaret Tucker; Angela Cecilia Pesatori; Neil E Caporaso; Pier Alberto Bertazzi; Maria Teresa Landi
Journal:  Am J Epidemiol       Date:  2010-01-04       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.